Clinical Trial Update: Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of capecitabine and vorinostat for recurrent/metastatic head and neck squamous cell carcinomas was terminated, with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hypopharyngeal Squamous Cell Carcinoma
• Laryngeal Squamous Cell Carcinoma
• Oral Cavity Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma
• Paranasal Sinus Squamous Cell Carcinoma

Drugs mentioned

• Xeloda (capecitabine) (capecitabine)
• Zolinza (vorinostat) (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Paranasal Sinus Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2017-04-14